Cytokinetics, Incorporated awaits a pivotal FDA decision on aficamten for hypertrophic cardiomyopathy. Learn more about CYTK ...
System of Care to Advance Care for the Most Commonly Inherited Heart DiseaseSOUTH SAN FRANCISCO, Calif., (GLOBE NEWSWIRE) -- ...
BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc. (“Imbria”), a clinical-stage company transforming cardiovascular disease therapeutics by targeting cardiac energy metabolism, ...
Three Late Breaking Science Presentations from MAPLE-HCM Provide Additional Data Including Responder Analyses, Patient Reported Outcomes, and Cardiac Biomarkers ...
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported a management update and financial results for the third quarter of 2025. Continued to ...
Advances development of ninerafaxstat, a potential first-in-class therapy designed to improve cardiac energetics in patients with serious cardiovascular diseases Enrollment underway across U.S. sites ...
Bristol Myers Squibb currently has the only drug approved specifically for treating obstructive hypertrophic cardiomyopathy, a debilitating disorder that can progress to heart failure. But safety ...
Cytokinetics may be counting down the days until the FDA decides whether to approve its cardiovascular drug aficamten. | ...
Lexicon Pharmaceuticals targets a turnaround with sotagliflozin, LX9851, pilavapadin, and partnerships offering multiple ...
BMY shares drop after halting the Librexia ACS trial, though other milvexian studies continue with top-line data expected in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback